We have shown that the pulsing of dendritic cells ( DCs ) with human papillomavirus type 16 ( HPV -16 ) antigen proteins by lipofection stimulates class I -restricted cytotoxic T lymphocyte ( CTL ) response against primary cervical cancer cells. Also, we have shown that adeno -associated virus ( AAV ) was able to effectively deliver a cytokine gene into DCs. It has been our hypothesis that the delivery of antigen genes into DCs, resulting in endogenous and continuous antigen protein expression, may result in an improvement in T -cell priming by DCs. Here, DCs are pulsed ( infected ) with an AAV vector containing the HPV -16 E6 gene. After infection, transduced E6 gene mRNA expression and vector chromosomal integration could be identified in infected DCs. Furthermore, priming rosettes formed at early times when the AAV / E6 vector was used. Most importantly, AAV / E6 vector pulsing of DCs induced, after only 7 days of priming, a strong CTL response against primary cervical cancer cell lines, compared to bacterial E6 protein lipofection. Killing was significantly blocked by the addition of anti -MHC class I antibodies. Fluorescence -activated cell sorter ( FACS ) analysis of resulting primed cell populations revealed higher levels of CD8 + T cells by AAV -based pulsing, with little evidence of CD56 ( NK ). FACS analysis of the DC populations revealed that AAV / E6 vector -pulsed DCs had higher levels of CD80 and lower levels of CD86 than protein -pulsed DCs. These data suggest that rAAV may be appropriate for antigen pulsing of DCs for immunotherapy protocols. Finally, our protocol represents an advance in regards to the time needed for generating a CTL response compared to other techniques. Cancer Gene Therapy ( 2001 ) 8, 948 -957 
O ne approach toward developing an effective immunotherapeutic regime for certain cancers and infectious diseases may be through the manipulation of antigenpresenting cells, such as dendritic cells (DCs ). DCs are potent, professional antigen -presenting cells, which are able to initiate primary immune response to antigens by naive T cells. 1 Their manipulation could correct immune defectiveness or tumor tolerance, resulting in effective DC or primed T-cell adoptive immunotherapies. Recently, highly effective tissue culture protocols for generating DCs in vitro from peripheral blood have been developed. This ability to produce significant quantities of DCs allows for the possibility of their in vitro manipulation for clinical protocols. 2, 3 Many groups are, in fact, developing protocols for DC manipulation, in which specific cytotoxic T lymphocyte ( CTL ) responses against tumor cells ( in vitro ), or tumor challenge (in vivo ), can be generated by pulsing DCs with tumor fragments, antigen peptides, defined tumor antigens, or with antigen genes by way of retrovirus and adenovirus vectors. 4 -35 There are several potential ways to treat or pulse cells with proteins; however, all proteins degrade. For example, human papillomavirus (HPV ) E7, which can serve as a target antigen for cervical cancer, has a half -life of only 1 hour. 36 We and others have hypothesized that a more effective technique for treating DCs might be the internal generation of the antigen protein in situ, within the DC itself. By delivering the tumor antigen gene directly into DCs, a stable and continuous production of the tumor antigen can be accomplished. 8, 9, 11, 12, 18, 24, 26, 29, 30 Adeno -associated virus ( AAV ) has been shown to be an effective gene -delivery vector for both immortalized tissue culture cells as well as primary hematopoietic cells. 37 -48 Previously, we have demonstrated the successful transduction, including chromosomal integration, of the GM -CSF gene into monocytes ( Mos ) and DCs. 37 AAV-based transduction of the GM -CSF gene was found to be able to fully replace the need for the standard addition of exogenous GM -CSF in pre -DC cultures. This was the first study to demonstrate AAVmediated gene transduction specifically into DCs. We believe that AAV, with its virion composed of a very limited repertoire of proteins, and its ability to chromosomally integrate, may be useful for antigen gene delivery into DCs.
In this study, we demonstrated the successful transduction of the HPV-16 E6 antigen gene into DCs, resulting in significant MHC class I-restricted cervical cancer cell killing activity. Furthermore, it is demonstrated that the length of priming, the time of DC -T cell incubation, with this AAV-transduction technique, requires only 1 week to generate significant killing activity. This is in sharp contrast to antigen protein lipofection of DCs, which usually requires 2 -3 weeks incubation. 34, 35 
MATERIALS AND METHODS
Construction of the AAV /E6 / Neo genome, generation of virus stocks, and titering of virus stocks. The AAV /E6 /Neo genome was constructed as a plasmid, in a similar manner to the construction of the AAV /GM -CSF /Neo viral genome previously described. 37 However, instead of the GM -CSF gene, the HPV-16 E6 open reading frame was cloned by PCR amplification using Pfu polymerase and ligated into the vector. High -titer rough ( nonpurified ) rAAV virus stocks were generated in a two -step process, using the complementor plasmid ins96 -0.8, and titered as described previously. 37, 49 To generate purified rAAV virus the technique described by Auricchio et al 50 was used. Briefly, the virus solution treated by DNase I ( Promega Co., Madison, WI ) was incubated with 0.5% deoxycholic acid ( Sigma, St. Louis, MO ) for 30 minutes at 378C. After filtration the solution was applied on a heparin-agarose column ( Sigma ). The matrix was washed twice with 25 mL of 0.254 M NaClphosphate -buffered saline (PBS ), pH 7.4, and then eluted with 15 mL of 0.554 M NaCl -PBS, pH 7.4. The eluate was then concentrated to about 1 mL using a Millipore Biomax -100 K NMWL filter device and centrifugation. 50 Purity of the viral preparation ( 100 L ) was assessed on 4 -20% SDS -polyacrylamide gel run. The proteins were detected by Coomassie staining. The titer of purified virus was calculated by dot blot and determined to be 1Â10 11 encapsidated genomes per milliliter. Cells used in this study. The primary cervical cancer cell lines, CA1 (patient 1 ) and CA2 ( patient 2 ), have been described previously, both containing HPV-16 DNA, and were approximately 10 passages from initial isolation. 34 These cells were grown in keratinocyte-SFM supplemented with epidermal growth factor and bovine pituitary extract ( Gibco BRL /Life Technologies, Rockville, MD ). Human leukocyte antigen (HLA ) typing of these cells gave haplotypes of HLA A1 for both CA1 and CA2, respectively. Mos and DCs were derived from peripheral blood mononuclear cells ( PBMCs). PBMCs were separated by routine Ficoll gradient method from fresh blood drawn from healthy persons. The normal donor had a haplotype of HLA A1, compatible with the target cancer cells. The PBMCs were inoculated into six -well culture plates and incubated with 2 mL of AIM -V medium for 2 hours at 378C and 5% CO 2 . At that time, nonadherent cells were removed by carefully washing the monolayer three times with PBS, pH 7.0. Infection of Mo /DCs with AAV virus and treatment with cytokines. Immediately after the removal of the nonadherent cells, the adherent Mos were infected (pulsed) with 0.5 mL of virus stock ($5Â10 10 encapsidated genomes) when using the nonpurified virus, or 10 7 encapsidated genomes when using the purified virus. After 2 hours incubation the medium /virus solution was removed, the cells were washed with AIM -V, and finally fed with AIM -V medium. The infection protocol is outlined in Figure 1D . The Mo /DC precursors were infected with 0.5 mL of virus stock or lysate at days 0, 3, and 5. Throughout this time, the Mo /DC culture was treated with human GM -CSF ( LEUKINE 1 , Immunex, Seattle, WA, 1.4Â10 6 IU /250 g) at a final concentration of 800 IU /mL. At day 3, to induce the maturation of Mos into DCs, human interleukin ( IL ) 4 (IL -4, R&D Systems, Minneapolis, MN ) at 1000 IU /mL was added to the medium. Finally, at day 5, recombinant human IL -2 ( R&D Systems) at 10 U /mL was added.
Generation of bacterial E6 protein and lipofection of Mo /DCs. GST-E6 protein was generated in a similar manner to previous generation of GST-E7. 34 The Mo /DCs were lipofected ( pulsed ) with 50 g of GST-E6 on day 5 as previously described. 34 The treatment of the protein pulsed Mo /DCs with cytokines was the same as that of the virusinfected DCs.
mRNA isolation and RT-PCR analysis for E6 expression. E6 mRNA expression was measured by RT-PCR amplification along with a cellular mRNA control. Total RNA was isolated from mock ( lysate )-infected and AAV / E6 / Neo -infected Mo /DCs using Trizol reagent ( Gibco BRL /Life Technologies ), according to the manufacturer's protocol, and treated with 5 U / g of RNase -free DNase I ( Promega) at 378C for 1 hour. Messenger RNA was then separated using the Oligotex mRNA Mini Kit (Qiagen, Valencia, CA ) according to the supplier's instruction. The first-strand cDNA synthesis was performed at 378C for 1 hour in a final volume of 25 L reaction buffer [ 1 g mRNA; 50 mM Tris -HCl, pH 8.3; 75 mM KCl; 3 mM MgCl 2 ; 10 mM DTT; 0.5 g oligo( dT ) 15 ( Promega); 0.5 mM each of the four dNTPs; 30 U of RNasin ( Promega ) and 200 U of M -MLV reverse transcriptase RNase H Minus ( Promega)] . PCR amplification of the cDNA was performed in 100 L reaction volume, which contained 2.5 U Taq DNA polymerase ( Fisher Scientific, Pittsburgh, PA ); 10 mM Tris -HCl, pH 8.3; 50 mM KCl; 2 mM MgCl 2 ; 0.2 mM each of the four dNTPs; 1 M of each upstream and downstream primer specific for the cDNA template and 10 L cDNA template. The E6 primer set used was 5 0 -ACCACAGT-TATGCACAGAGC -3 0 and 5-AGGACACAGTGGCTTTT-GAC -3 0 , which targeted amplification of the HPV-16 sequences from nt 139 to 420. A control RT-PCR analysis of expression of the housekeeping gene TFIIB was also undertaken with the primer set 5 0 -GTGAAGATGGCGTC-TACCAG -3 0 and 5 0 -GCCTCAATTTATAGCTGTGG -3 0 , which amplified nt 356 -1314 of that mRNA. To ensure that DNA was not contributing to the results, a direct PCR was also undertaken. The products were then analyzed on an agarose gel, stained with ethidium bromide, and visualized by ultraviolet light.
Intracellular staining for E6. This protocol is adapted from that described by Pala et al 51 The Mo /DCs were infected with virus or lipofected with protein as described above. Cells were then treated with IL -4 and GM -CSF under standard conditions. Seven days after infection /lipofection the cells were harvested, washed, and fixed with 2% paraformaldehyde in PBS for 20 minutes at room temperature. The cells were washed and permeabilized with PBS / 1% BSA /0.5% saponin ( S-7900, Sigma) for 10 minutes at room temperature. Cells were stained with anti -HPV-16 /18 E6 (Chemicon, Temecula, CA; cat. no. MAB874) plus FITC -anti -mouse-Ig ( Becton Dickinson, cat. no. 554001 ) and analyzed by flow cytometry. Detection of viral integration by PCR /Southern blot analysis. Chromosomal integration of the AAV /E6 /Neo genome was undertaken by vector -chromosome junction PCR amplification and Southern blot analysis as previously described. 37 Chromium release assay of CTL activity. Nonadherent PBMCs ( T cells and B cells ) were washed and resuspended in AIM -V at ( 10-20 )Â10
6 cells /well in six -well culture plates ( Costar, Cambridge, MA ) with rAAV-or GST-E6 -pulsed DCs ( ratios from 20:1, responders:dendritic ). The cultures were supplemented with recombinant human GM -CSF (800 U /mL ) and recombinant human IL -2 (10 U /mL ). At 7 days post addition of the PBMCs, the cells were assayed for tumor cell killing activity in a 6-hour chromium -51 release assay as previously described. 34 One of two HLA class I A1 -compatible primary cervical tumor cells was 51 Cr-labeled and used as targets as previously described. 34 To determine the structures on the target cells involved in lysis, anti -class I monoclonal antibodies ( mAbs ) were used to block cytotoxicity. The 51 Cr-labeled tumor targets were preincubated with mAbs specific for monomorphic HLA class I W6/ 32 (50 g /mL ) (hybridoma obtained from the ATCC, Rockville, MD ). The effector cells and 51 Cr-labeled targets were then incubated in a final volume of 200 L for 6 hours at 378C with 5% CO 2 .
Cell surface marker analysis of T cells and DCs by fluorescent antibody cell sorting (FACS ). For the analysis of T cells, at day 12 of the experiment the primed T-cell populations were analyzed for surface markers. A panel of mAbs recognizing the following antigens was used: anti-CD4, anti -CD8, anti -CD56 (Pharmingen, San Diego, CA ). Control irrelevant isotype -matched FITC -or PE -conjugated mAbs were obtained from Becton Dickinson. These cells were greater than 95% viable as assessed by trypan blue exclusion. Cell suspensions were counted and distributed into 12Â75-mm tubes. Mouse mAbs were diluted in cold assay buffer and the final pellet was resuspended in 500 -L volume. Tubes were incubated for 30 minutes followed by two washes with assay buffer and the final cell pellet was resuspended in 500 L of assay buffer for subsequent analysis. Cells were analyzed with a fluorescence -activated cell sorter (FACS; Becton Dickinson ) with a 15 -mW argon laser with an excitation of 488 nm. Fluorescent signals were gated on the basis of cell dimension (i.e., forward and right angle light scattering typical of PBL activated. Gated signals ( 5,000 -10,000 ) were detected at 585 BP filter and analyzed using Cell Quest software (Becton Dickinson, Bedford, MA ).
For the analysis of DCs, a panel of mAbs recognizing the following antigens was used: anti -CD40 (Immunotech, Marseille, France ); anti -CD14, anti -DR, anti -CD80 (Becton Dickinson ), anti -CD86 (Pharmingen, San Diego, CA ), anti -CD83 (Coulter, Miami, FL ). Control irrelevant isotype -matched FITC -or PE -conjugated mAbs were obtained from Becton Dickinson. Briefly, nonadherent cells were harvested by washing the plates with PBS, pH 7.2 ( Gibco ). Adherent cells were recovered by incubating the plates at room temperature for 15-20 minutes in the presence of Ca + and Mg + -free PBS, followed by gentle scraping. These cells were > 95% viable as assessed by trypan blue exclusion. Cell suspensions were counted and distributed into 12Â75 mm tubes. Mouse mAbs were diluted in cold assay buffer (PBS, pH 7.2, supplemented with 0.I% FBS ) and added in a 50-L volume. For direct fluorescence, tubes were incubated for 30 minutes followed by two washes with assay buffer and the final cell pellet was resuspended in 500 L assay buffer for subsequent analysis.
RESULTS
Efficient transduction of Mo /DC precursors with an AAV / E6 /Neo virus. The purpose of this study was to determine if AAV-based antigen gene delivery into DCs was able to elicit a cytotoxic response, and if so, how did AAV pulsing compare with pulsing DCs by DOTAP -lipofection of an antigen protein? A structural map of the AAV / E6 /Neo vector used in this study is shown in Figure 1A . In this construct the E6 gene was expressed from the AAV p5 promoter, which is known to be active in DCs. 37 AAV /E6 / Neo virus stock was generated by a two -step process as we have done previously, and a comparison of various G418 resistant producer cell lines, by dot blot hybridization, is shown in Figure 1B . The titering of the nonpurified virus stock, in encapsidated genomes ( eg ) per milliliter of this virus stock, by dot blot hybridization is shown in Figure 1C ( about 10 11 eg/ mL ). Normally, freshly adherent Mos from peripheral blood are treated with GM -CSF and IL-4 to stimulate their differentiation into DCs. Our technique, designed for promoting AAV vector transduction in DC precursor Mos, has been to treat freshly adherent Mos with GM -CSF alone for several days. 37 This treatment, without IL -4, stimulates Mo proliferation and allows for higher AAV transduction rates. In these studies, three infections were undertaken as indicated in Figure 1D . After AAV infection and GM -CSF treatment, at day 3, the cells were finally treated with IL -4 to induce differentiation into DCs. We first analyzed the transduction of the Mo /DC population by observing RNA expression of the E6 transgene. Polyadenylated RNA was isolated from AAV / E6 /Neo -infected and mock -infected DC cultures at day 5 (after IL-4 introduction and differentiation into DCs ) and was analyzed for E6 mRNA by RT-PCR. Expression of the cellular TF II B gene was also undertaken as a control. The results, shown in Figure 2 demonstrate that E6 expression was only taking place in the virally infected DCs.
The efficiency of virus / gene and lipofection/ protein pulsing of Mo /DCs was analyzed and compared by intracellular staining. The cells were analyzed 4 days after pulsing. The results, shown in Figure 3 , demonstrate that AAV /E6 /Neo infection of Mos resulted in a much higher percentage of cells containing intracellular E6 protein than direct protein pulsing (72% to 29% ). We next observed chromosomal integration of the AAV / E6 /Neo vector in DCs. Chromosomal integration, although not essential for gene expression from AAV vectors, does signify a permanent genetic alteration of the DCs, and is a desirable ''gold standard'' for viral transduction. Chromosomal integration was demonstrated by PCR amplification of vector -chromosome junctions using primers complementary to the SV40 promoter within the vector and AluI repetitive chromosomal elements. DCs were similarly treated as in the RNA analysis experiments of Figure 2 . Junction products were analyzed by agarose gel electrophoresis, Southern blotted, and probed for Neo sequences. Neo was included within the vector in addition to E6. As shown in Figure 4 , multiple vector -chromosomal junction products were observed in the AAV / E6 /Neo -infected DCs, but not in mock -infected DCs. Unfortunately, the vector must integrate close to an AluI element to be identified by this technique. In any case, these data indicate that at least some of the viral genomes are able to chromosomally integrate in the DC population. (Fig 1D ) , and then induced to differentiate into DCs by IL -4. Similar DC cultures were pulsed with GST-E6 antigen protein using DOTAP ( see Materials and Methods ) on day 5. Later on day 5, after 2 days of IL -4 treatment, mixed T-cell populations were added back into the AAV / E6 /Neo -, DOTAP / GST-E6 protein -, and mock -pulsed DC cultures to allow priming. As AAV /antigen pulsing is novel, we observed these cultures on a daily basis. It was almost immediately noticed that cell clustering was taking place in an enhanced manner in the AAV-pulsed DC cultures relative to the protein -pulsed or lysate control cultures (Fig 5 ) . Upon examining the cell morphology present we believe these clusters to be due to T cell -DC rosetting. This caused us to speculate that the AAV pulsing of DCs might be allowing for more rapid priming of the T cells. We continued our observation of the AAV-pulsed cultures and observed that after 7 days of priming the rosettes were dispersing. We interpreted that this change was signaling the completion of priming and the subsequent death of the DCs as a target. This is in sharp contrast to the protein -and lysate-pulsed cultures, which still did not show extensive rosetting. Normally DC -T cell incubation and priming require 2 to 3 weeks to allow for significant CTL activity. AAV pulsing of DCs may require only 7 days of priming.
The ability of these 7 day -primed T cells to carry out class I-restricted recognition and killing of HLA A1 -matched primary cervical cancer cells was tested in chromium release assays. The previously characterized primary cervical cancer cell line 1, CA -1, was used as a target. 34 Our impression of rapid priming was fully borne out by the level of target killing. A representative experiment is shown in Figure 6 . Normally, protein / DOTAP pulsing of DCs results in significant target killing. 34 However, by allowing only a short period of priming, the percent killing resulting from this technique was only slightly above the cell lysate control (mock ). In sharp contrast, the AAV / E6 /Neo -pulsed -DC -primed T ctrl mock AAV/E6/Neo kb 6.7>
1.3> GST-E6 lipof-DC, 29% AAV/E6/Neo-DC, 72% cells resulted in much higher killing activity than the protein primed and lysate controls. These same AAV /E6 / Neo -primed cells were unable to lysis an unrelated multiple myeloma target. Finally, the addition of the anti -class I antibody W632 significantly blocked killing, indicating class I restriction of killing. We next assayed for class I-restricted killing of a second HLA A1 -matched, previously characterized primary cervical cancer cell line CA -2. 34 The resulting killing was very similar to that against CA -1 (Fig 6) . Again, the addition of the anticlass I antibody W632 significantly blocked killing, indicating class I restriction of killing. Finally, because we had utilized nonpurified virus in these experiments, which contained lysed cellular components, we repeated the CTL experiment using a heparin column -purified virus stock. DCs were pulsed with 10 7 purified encapsidated genomes of AAV /E6 /Neo (approximately 10 À 3 virus used in the Fig 6 experiments ) . A CTL assay was then carried out on the CA1 cervical cancer primary target as described in Figure 6 . The resulting killing for AAV / E6 /Neo, AAV /E6 /Neo plus anti -class I antibodies, GST-E6, and lysate control pulsing of DCs were 36.1 ± 1.4%, 0.4 ± 0.3%, 3.1 ± 1.4%, and 2.0 ± 0.5%, respectively. These data indicate that the CTL activity in all of these experiments was in fact due to AAV / E6 /Neo viral transduction /pulsing of DCs.
Higher CD8 / CD4 and lower CD56 / CD8 cell ratios result with AAV-mediated pulsing / priming. Next, the makeup of the T-cell populations, which resulted from AAV transduction or protein lipofection, was observed. An effective CTL response, while requiring CD8 + T cells as an effector of lysis, also requires CD4 + helper T cells. 52 We used flow cytometric analysis to determine the phenotype of the population of the lysate, GST-E6 -pulsed, and AAV /E6 / Neo -pulsed T-cell populations. As shown in Figure 7A , in the mock case, we see a normal ratio of CD8 to CD4 positive cells ( 1.21:1 ). In the GST-E6 pulsing case, the CD8 / CD4 ratio remains the same ( 1.23:1 ). In sharp contrast, in the AAV / E6 /Neo -pulsed case, the ratio of CD8 /CD4 changes dramatically to 7.0:1. Normally, one would not expect this high ratio to arise until 3 weeks of DC / T-cell priming, 34 suggesting that the AAV -Ag pulsing of DCs results in not only quicker activation, but also higher killing activity, HLA class I restricted, on a per CD8 + T-cell basis. The high killing is consistent with a Type 1 (Th 1 ) response. This is important because recent studies have suggested that progression to cervical cancer from precursor lesions may be associated with a preferential Type 2 ( Th 2) T-cell response, along with significant dysfunction of Type 1 T-cell response in patients with high -grade cervical intraepithelial lesions and invasive cervical cancer. 53 The expression of CD56 was also observed. Some consider this marker as being specific for natural killer T cells. 54 However, others have reported that some CD8 + T cells do express CD56 and do exhibit HLA class I -restricted killing. 55 Despite this confusion, all of our T-cell populations exhibited low CD56 expression. However, what is noteworthy in this analysis is the very high level of CD8 + T cells in the case of AAV / E6 /Neo pulsing, confirming the CD8 /CD4 analysis ( Fig 7A ) . Taken together, these data lysate-pulsed GST-E6 pulsed AAV/E6/Neo pulsed indicate a very different resulting primed T-cell population when AAV -antigen pulsing was used, and suggests that the increased killing activity may be a result of these changes in the T-cell population These data also indicate that CD8 is a specific lineage marker in HLA class I restriction in our system.
AAV/ E6 vector pulsing resulted in DCs with higher CD80, and lower CD86 expression. Finally, we characterized the DCs resulting from the various pulsing techniques to observe if significant differences were discernable. We used flow cytometric analysis to determine the phenotype of untreated, lysate -pulsed, GST-E6 -pulsed, and AAV /E6 /Neo -pulsed DC populations. The results, shown in Figures 8 and 9 , demonstrate that the DCs generated from all four techniques share all of the common DC markers. However, AAV / E6 / Neo -pulsed DCs did express significantly higher levels of CD80 and lower levels of CD86 than the GST-E6 -pulsed DCs. 
DISCUSSION
Cervical cancer is an ideal model system for investigating adoptive immunotherapy protocols as >90% of cervical cancers contain HPV DNA and the E6 and E7 oncoproteins are always expressed. We have hypothesized that antigen gene pulsing of DCs should be more effective than protein pulsing of DCs for several reasons. First, the continuous production of the antigen protein, by gene transfer, should result in higher cytotoxicity, as a result of preventing the loss antigenicity due to protein degradation, and of MHC class I and II protein cycling as happens with protein pulsing of DCs. Second, viral delivery of the antigen results in greater efficiency in DC pulsing as virus infection is usually more effective in delivery than the lipofection of proteins ( Fig 3 ) . Third, viral delivery of the antigen should result in higher epitope presentation in the context of class I molecules, which should result in more efficient activation of the CD8 + cytotoxic T cells than when antigen proteins are delivered via lipofection. 56 Fourth, the epitopes produced and expressed endogenously in DCs should be more representative and, thus, more immunoreactive, than epitopes of proteins produced in bacteria, as bacteria lack many of the posttranslational modifications seen in mammals. These rationales form the overall logic for this study. For this purpose, wild -type AAV is known to latently infect cells at high frequency, 57 -59 and recombinant AAV has been shown to be a versatile virus vector, being able to transduce a wide variety of cell types. 38 -49 This study demonstrates that AAV is able to transduce freshly adherent Mo /DC precursors, and that the transduction of E6 gene into DCs results in functionally active E6 -epitope -presenting DCs. Other viruses, including retroviruses, adenoviruses, and pox viruses, have previously been shown to transduce DCs. 9, 11, 24, 29, 30 However, to our knowledge, this is the first report of antigen gene transduction into human DCs by AAV. AAV can transduce by chromosomal integration and we have found that this is also possible for AAV transduction of DCs. The strength of priming found in this study suggests that AAV-transduced DCs do have a higher immunologic profile than the AAVtransduced cells of other studies. We believe that the increased DC -T cell rosetting when using the AAV vector is consistent with this hypothesis. However, this is not surprising due to the effective nature of DCs as professional antigen-presenting cells.
It was surprising that the AAV -antigen pulsing technique resulted in the extremely fast priming of T cells with only 1 week of DC -T cell incubation. FACS analysis of the resulting T-cell populations suggests that the difference is likely due to an increase in proliferation of antigen -specific CD8 + T cells ( Fig 6A ) . Little evidence of CD56 expression, and therefore, NK activity, was found. Furthermore, the AAV / E6 /Neo -pulsed DCs did express higher levels of CD80, and lower levels of CD86, than the protein -pulsed DCs. As CD80 is believed to be a more independent costimulatory molecule than CD86, this may explain the improve capabilities of the vector-transduced DCs. 60 Overall, these data suggest that the efficiency of AAV-mediated antigen gene delivery into Mo /DCs is quite good. Our protocol represents a breakthrough compared to other DCpulsing protocols in which the priming step requires 2 or 3 weeks, or more, of incubation. Even if the observed fast priming by AAV /E6 / Neo is mechanistically unclear, our data suggest that rAAV may be a highly effective vector for delivering antigen genes into DCs and eliciting immune response.
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